Coincidence of Bullous Pemphigoid and Pityriasis Rubra Pilaris

Authors

  • Irina Gasslitter Dermatology, venereology and allergy, Medical University of Innsbruck, Innsbruck, Austria
  • Judith Löffler-Ragg Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria
  • Enno Schmidt Department for Dermatology, University of Lübeck, Lübeck, Germany
  • Matthias Schmuth Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria
  • Robert Gruber Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria

DOI:

https://doi.org/10.2340/actadv.v102.1289

Keywords:

Bullous pemphigoid, pityriasis rubra pilaris, BP180, LAD-1, intravenous immunoglobulin

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.

https://doi.org/10.1016/S0140-6736(12)61140-4

Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol 2018; 54: 26-51.

https://doi.org/10.1007/s12016-017-8633-4

Chaudhary R, Chaudhary N. A 45-year-old woman with erythroderma and bullous eruption: erythrodermic bullous pemphigoid. J Pharm Biomed Sci 2018; 8: 94-97.

Genovese G, Muratori S, Berti E, Marzano AV. Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid. Clin Exp Dermatol 2019; 44: 73-75.

https://doi.org/10.1111/ced.13718

Miyashita K, Iioka H, Miyagawa F, Ishii N, Hashimoto T, Asada H. A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230. Eur J Dermatol 2018: 28: 248-250.

https://doi.org/10.1684/ejd.2018.3229

Schulze F, Neumann K, Recke A, Zillikens D, Linder R, Schmidt E. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol 2015; 135: 1445-1447.

https://doi.org/10.1038/jid.2014.547

Goto-Hamano H, Ito K, Sakamoto-Kumura K, Terui T, Ohyama B, Hashimoto T, Hara H. Autoantibodies against multiple epitopes in Bp180 and laminin gamma-1 in subepidermal blistering skin disease associated with psoriatic erythroderma. Indian J Dermatol 2015; 60: 521.

https://doi.org/10.4103/0019-5154.164433

Roeder C, Driesch PV. Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. Eur J Dermatol 1999; 9: 537-539.

Kerr AC, Ferguson J. Type II adult-onset pityriasis rubra pilaris successfully treated with intravenous immunoglobulin. Br J Dermatol 2007; 156: 1055-1056.

https://doi.org/10.1111/j.1365-2133.2007.07773.x

Hoffmann JHO, Enk AH. High-Dose Intravenous Immunoglobulin in skin autoimmune disease. Front Immunol 2019; 10: 1090.

https://doi.org/10.3389/fimmu.2019.01090

Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol 2017; 77: 845-854.e5.

https://doi.org/10.1016/j.jaad.2017.07.013

Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-854.

https://doi.org/10.1111/bjd.12214

Downloads

Published

2022-03-22

How to Cite

Gasslitter, I., Löffler-Ragg, J. ., Schmidt, E., Schmuth, M., & Gruber, R. (2022). Coincidence of Bullous Pemphigoid and Pityriasis Rubra Pilaris. Acta Dermato-Venereologica, 102, adv00674. https://doi.org/10.2340/actadv.v102.1289

Issue

Vol. 102 (2022)

Section

Short Communication

Categories

License

Copyright (c) 2022 Irina Gasslitter, Judith Löffler-Ragg, Enno Schmidt, Matthias Schmuth, Robert Gruber

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.